# Chronic Lymphocytic Leukemia — Fifth Annual National General Medical Oncology Summit Page: https://stenobird.com/podcast/hematologic-oncology-update-916423/chronic-lymphocytic-leukemia-fifth-annual-national-general-medical-oncology-summit Text version: https://stenobird.com/podcast/hematologic-oncology-update-916423/chronic-lymphocytic-leukemia-fifth-annual-national-general-medical-oncology-summit.md Podcast: [Hematologic Oncology Update](https://stenobird.com/podcast/hematologic-oncology-update-916423) Published: 2026-06-16T21:00:00+00:00 Episode link: https://hematologic-oncology.captivate.fm/episode/6009-gmo26-cll Audio file: https://dts.podtrac.com/redirect.mp3/episodes.captivate.fm/episode/527dbe51-b818-4f92-aaa3-ddfb130c2966.mp3 Processing state: not_requested JSON: https://stenobird.com/v1/public/podcasts/hematologic-oncology-update-916423/episodes/chronic-lymphocytic-leukemia-fifth-annual-national-general-medical-oncology-summit Duration seconds: 3324 ## Resource Featuring perspectives from Dr John N Allan and Dr Adam Kittai, including the following topics: Introduction (0:00) Current Management of Newly Diagnosed Chronic Lymphocytic Leukemia — Dr Allan (8:47) Noncovalent Bruton Tyrosine Kinase Inhibitors and Other Novel Strategies — Dr Kittai (38:14) CME information and select publications ## Actions - request_transcript: `POST https://stenobird.com/v1/public/podcasts/hematologic-oncology-update-916423/episodes/chronic-lymphocytic-leukemia-fifth-annual-national-general-medical-oncology-summit/transcription-requests` — Idempotently request low-priority transcript generation for this episode. - read_markdown: `GET https://stenobird.com/podcast/hematologic-oncology-update-916423/chronic-lymphocytic-leukemia-fifth-annual-national-general-medical-oncology-summit.md` — Read the agent-friendly Markdown representation of this episode resource. A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed. ## Transcript Full transcripts are not published on public pages unless there is a clear rights basis.